Overview

Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

Status:
Terminated
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if implitapide, used in conjunction with other lipid-lowering therapies, is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolemia (HeFH).
Phase:
Phase 2
Details
Lead Sponsor:
Medical Research Laboratories International